Distinct Clinical and Prognostic Features of Myelodysplastic Syndrome in Patients from the Middle East, North Africa, and Beyond: A Systemic Review

Amal Al-Haidose; Mohamed A Yassin; Muna N Ahmed; Hasna H Kunhipurayil; Asrar A Al-Harbi; Musheer A Aljaberi; Saddam A Abbasi; Shahram Kordasti; Atiyeh M Abdallah

doi:10.3390/jcm12082832

Distinct Clinical and Prognostic Features of Myelodysplastic Syndrome in Patients from the Middle East, North Africa, and Beyond: A Systemic Review

Amal Al-Haidose, Mohamed A Yassin, Muna N Ahmed, Hasna H Kunhipurayil, Asrar A Al-Harbi, Musheer A Aljaberi, Saddam A Abbasi, Shahram Kordasti, Atiyeh M Abdallah

Comprehensive Cancer Centre

Research output: Contribution to journal › Review article › peer-review

Abstract

Myelodysplastic syndrome (MDS) describes a group of bone marrow malignancies with variable morphologies and heterogeneous clinical features. The aim of this study was to systematically appraise the published clinical, laboratory, and pathologic characteristics and identify distinct clinical features of MDS in the Middle East and North Africa (MENA) region. We conducted a comprehensive search of the PubMed, Web of Science, EMBASE, and Cochrane Library databases from 2000 to 2021 to identify population-based studies of MDS epidemiology in MENA countries. Of 1935 studies, 13 independent studies published between 2000 and 2021 representing 1306 patients with MDS in the MENA region were included. There was a median of 85 (range 20 to 243) patients per study. Seven studies were performed in Asian MENA countries (732 patients, 56%) and six in North African MENA countries (574 patients, 44%). The pooled mean age was 58.4 years (SD 13.14; 12 studies), and the male-to-female ratio was 1.4. The distribution of WHO MDS subtypes was significantly different between MENA, Western, and Far East populations ( n = 978 patients, p < 0.001). More patients from MENA countries were at high/very high IPSS risk than in Western and Far East populations (730 patients, p < 0.001). There were 562 patients (62.2%) with normal karyotypes and 341 (37.8%) with abnormal karyotypes. Our findings establish that MDS is prevalent within the MENA region and is more severe than in Western populations. MDS appears to be more severe with an unfavorable prognosis in the Asian MENA population than the North African MENA population.

Original language	English
Article number	2832
Journal	Journal of Clinical Medicine
Volume	12
Issue number	8
DOIs	https://doi.org/10.3390/jcm12082832
Publication status	Published - 12 Apr 2023

Access to Document

10.3390/jcm12082832

Cite this

Al-Haidose, A., Yassin, M. A., Ahmed, M. N., Kunhipurayil, H. H., Al-Harbi, A. A., Aljaberi, M. A., Abbasi, S. A., Kordasti, S., & Abdallah, A. M. (2023). Distinct Clinical and Prognostic Features of Myelodysplastic Syndrome in Patients from the Middle East, North Africa, and Beyond: A Systemic Review. Journal of Clinical Medicine, 12(8), [2832]. https://doi.org/10.3390/jcm12082832

@article{bc1fbf857d914c2f8724aa127fd3f078,

title = "Distinct Clinical and Prognostic Features of Myelodysplastic Syndrome in Patients from the Middle East, North Africa, and Beyond: A Systemic Review",

abstract = "Myelodysplastic syndrome (MDS) describes a group of bone marrow malignancies with variable morphologies and heterogeneous clinical features. The aim of this study was to systematically appraise the published clinical, laboratory, and pathologic characteristics and identify distinct clinical features of MDS in the Middle East and North Africa (MENA) region. We conducted a comprehensive search of the PubMed, Web of Science, EMBASE, and Cochrane Library databases from 2000 to 2021 to identify population-based studies of MDS epidemiology in MENA countries. Of 1935 studies, 13 independent studies published between 2000 and 2021 representing 1306 patients with MDS in the MENA region were included. There was a median of 85 (range 20 to 243) patients per study. Seven studies were performed in Asian MENA countries (732 patients, 56%) and six in North African MENA countries (574 patients, 44%). The pooled mean age was 58.4 years (SD 13.14; 12 studies), and the male-to-female ratio was 1.4. The distribution of WHO MDS subtypes was significantly different between MENA, Western, and Far East populations ( n = 978 patients, p < 0.001). More patients from MENA countries were at high/very high IPSS risk than in Western and Far East populations (730 patients, p < 0.001). There were 562 patients (62.2%) with normal karyotypes and 341 (37.8%) with abnormal karyotypes. Our findings establish that MDS is prevalent within the MENA region and is more severe than in Western populations. MDS appears to be more severe with an unfavorable prognosis in the Asian MENA population than the North African MENA population. ",

author = "Amal Al-Haidose and Yassin, {Mohamed A} and Ahmed, {Muna N} and Kunhipurayil, {Hasna H} and Al-Harbi, {Asrar A} and Aljaberi, {Musheer A} and Abbasi, {Saddam A} and Shahram Kordasti and Abdallah, {Atiyeh M}",

note = "Funding Information: This publication was supported by Qatar University, internal grants no. QUCP-CHS-2022-551 and QUST-1-CHS-2023-838, Qatar University. The findings achieved herein are solely the responsibility of the authors. Publisher Copyright: {\textcopyright} 2023 by the authors.",

year = "2023",

month = apr,

day = "12",

doi = "10.3390/jcm12082832",

language = "English",

volume = "12",

journal = "Journal of Clinical Medicine",

issn = "2077-0383",

publisher = "MDPI",

number = "8",

}

TY - JOUR

T1 - Distinct Clinical and Prognostic Features of Myelodysplastic Syndrome in Patients from the Middle East, North Africa, and Beyond

T2 - A Systemic Review

AU - Al-Haidose, Amal

AU - Yassin, Mohamed A

AU - Ahmed, Muna N

AU - Kunhipurayil, Hasna H

AU - Al-Harbi, Asrar A

AU - Aljaberi, Musheer A

AU - Abbasi, Saddam A

AU - Kordasti, Shahram

AU - Abdallah, Atiyeh M

N1 - Funding Information: This publication was supported by Qatar University, internal grants no. QUCP-CHS-2022-551 and QUST-1-CHS-2023-838, Qatar University. The findings achieved herein are solely the responsibility of the authors. Publisher Copyright: © 2023 by the authors.

PY - 2023/4/12

Y1 - 2023/4/12

N2 - Myelodysplastic syndrome (MDS) describes a group of bone marrow malignancies with variable morphologies and heterogeneous clinical features. The aim of this study was to systematically appraise the published clinical, laboratory, and pathologic characteristics and identify distinct clinical features of MDS in the Middle East and North Africa (MENA) region. We conducted a comprehensive search of the PubMed, Web of Science, EMBASE, and Cochrane Library databases from 2000 to 2021 to identify population-based studies of MDS epidemiology in MENA countries. Of 1935 studies, 13 independent studies published between 2000 and 2021 representing 1306 patients with MDS in the MENA region were included. There was a median of 85 (range 20 to 243) patients per study. Seven studies were performed in Asian MENA countries (732 patients, 56%) and six in North African MENA countries (574 patients, 44%). The pooled mean age was 58.4 years (SD 13.14; 12 studies), and the male-to-female ratio was 1.4. The distribution of WHO MDS subtypes was significantly different between MENA, Western, and Far East populations ( n = 978 patients, p < 0.001). More patients from MENA countries were at high/very high IPSS risk than in Western and Far East populations (730 patients, p < 0.001). There were 562 patients (62.2%) with normal karyotypes and 341 (37.8%) with abnormal karyotypes. Our findings establish that MDS is prevalent within the MENA region and is more severe than in Western populations. MDS appears to be more severe with an unfavorable prognosis in the Asian MENA population than the North African MENA population.

AB - Myelodysplastic syndrome (MDS) describes a group of bone marrow malignancies with variable morphologies and heterogeneous clinical features. The aim of this study was to systematically appraise the published clinical, laboratory, and pathologic characteristics and identify distinct clinical features of MDS in the Middle East and North Africa (MENA) region. We conducted a comprehensive search of the PubMed, Web of Science, EMBASE, and Cochrane Library databases from 2000 to 2021 to identify population-based studies of MDS epidemiology in MENA countries. Of 1935 studies, 13 independent studies published between 2000 and 2021 representing 1306 patients with MDS in the MENA region were included. There was a median of 85 (range 20 to 243) patients per study. Seven studies were performed in Asian MENA countries (732 patients, 56%) and six in North African MENA countries (574 patients, 44%). The pooled mean age was 58.4 years (SD 13.14; 12 studies), and the male-to-female ratio was 1.4. The distribution of WHO MDS subtypes was significantly different between MENA, Western, and Far East populations ( n = 978 patients, p < 0.001). More patients from MENA countries were at high/very high IPSS risk than in Western and Far East populations (730 patients, p < 0.001). There were 562 patients (62.2%) with normal karyotypes and 341 (37.8%) with abnormal karyotypes. Our findings establish that MDS is prevalent within the MENA region and is more severe than in Western populations. MDS appears to be more severe with an unfavorable prognosis in the Asian MENA population than the North African MENA population.

UR - http://www.scopus.com/inward/record.url?scp=85154591095&partnerID=8YFLogxK

U2 - 10.3390/jcm12082832

DO - 10.3390/jcm12082832

M3 - Review article

C2 - 37109168

SN - 2077-0383

VL - 12

JO - Journal of Clinical Medicine

JF - Journal of Clinical Medicine

IS - 8

M1 - 2832

ER -

Distinct Clinical and Prognostic Features of Myelodysplastic Syndrome in Patients from the Middle East, North Africa, and Beyond: A Systemic Review

Abstract

Access to Document

Other files and links

Fingerprint

Cite this